Intelligent Thiosuccinyl-Crosslinked Hemoglobin Conjugate Delivery Systems

A next-generation thiosuccinyl-crosslinked hemoglobin conjugate delivery system that leverages wearable devices, implantable technology, and machine learning algorithms to provide personalized, adaptive treatment for various diseases.

The original patent disclosed pegylated thiosuccinyl-crosslinked hemoglobin conjugates for repeated doses or prolonged exposure. However, these conjugates have limitations in terms of controlled release, targeted delivery, and patient-specific treatment. The new inventive concept addresses these limitations by envisioning a system that integrates wearable devices, implantable technology, and machine learning algorithms to provide real-time monitoring and adaptive treatment.

The new inventive concept comprises a system for delivering thiosuccinyl-crosslinked hemoglobin conjugates to a patient, featuring a wearable device that releases the conjugates in response to physiological signals, and a control unit that adjusts the release rate based on real-time monitoring of the patient's condition. Additionally, the system may incorporate an implantable device that releases the conjugates in a pulsatile manner, mimicking the body's natural circadian rhythm. The conjugates themselves may be designed to target different tissues or cell types in the body, and may be synthesized using a microfluidic device that enables high-throughput synthesis and purification.

The new inventive concept introduces a paradigm shift in thiosuccinyl-crosslinked hemoglobin conjugate delivery by integrating wearable devices, implantable technology, and machine learning algorithms. This integration enables real-time monitoring and adaptive treatment, which is not possible with the original patent's conjugates. The use of microfluidic devices for high-throughput synthesis and purification of the conjugates is also a novel aspect of the inventive concept.

Alternative embodiments of the inventive concept may include using different types of wearable devices or implantable technology, such as implantable sensors or actuators. The conjugates may also be designed to target different diseases or conditions, such as cancer or inflammatory disorders. Furthermore, the system may be adapted for use in veterinary medicine or other fields.

The new inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of personalized medicine and targeted therapy. The market for wearable devices and implantable technology is growing rapidly, and the integration of these technologies with thiosuccinyl-crosslinked hemoglobin conjugates could lead to a significant shift in the treatment of various diseases.